Cipla (LUX:CIPLA) Inventories, Raw Materials & Components: $224 Mil (As of Mar. 2026)


LUX:CIPLA Cipla Ltd LUX:CIPLA
94 GF Score
Price $18.10
GF Value $19.69
! 5 Warning Signs
View Full Analysis

What is Cipla Inventories, Raw Materials & Components?

Cipla LUX:CIPLA 94 Inventories, Raw Materials & Components is $224 Mil as of Mar. 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 94/100 and a GF Value™ of $19.69. The stock has 5 warning signs investors should review.

Cipla's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $224 Mil.

Cipla's quarterly raw materials stayed the same from Sep. 2025 ($0 Mil) to Dec. 2025 ($0 Mil) but then increased from Dec. 2025 ($0 Mil) to Mar. 2026 ($224 Mil).

Cipla's annual raw materials declined from Mar. 2024 ($216 Mil) to Mar. 2025 ($216 Mil) but then increased from Mar. 2025 ($216 Mil) to Mar. 2026 ($224 Mil).

Cipla Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Cipla's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Inventories, Raw Materials & Components Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 254.44 217.92 216.01 215.60 223.68

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 215.60 0.00 0.00 0.00 223.68
LUX:CIPLA
94GF Score
Cipla Ltd LUX:CIPLA
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $224 Mil mean?
Cipla (LUX:CIPLA) has a Inventories, Raw Materials & Components of $224 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Cipla and its competitors.
Is Cipla's Inventories, Raw Materials & Components too high?
Cipla's current Inventories, Raw Materials & Components is $224 Mil. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Inventories, Raw Materials & Components compare to ZTS and UTHR?
Cipla's Inventories, Raw Materials & Components of $224 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Cipla and its competitors. Cipla's current Inventories, Raw Materials & Components is $224 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Inventories, Raw Materials & Components of $224 Mil. The stock's GF Value™ is $19.69, compared to a current price of $18.10 — trading 8.1% below its estimated fair value. The current Inventories, Raw Materials & Components is $224 Mil. Cipla's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Inventories, Raw Materials & Components is $224 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.1% below its estimated GF Value™ of $19.69.

Key valuation signals for LUX:CIPLA:

  • Inventories, Raw Materials & Components: $224 Mil
  • GF Value™: $19.69 vs. price of $18.10 (8.1% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
94GF Score

Get the complete analysis for LUX:CIPLA

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.69
GF Value